HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis

Magda Zanelli 1,*, Luca Stingeni 2, Maurizio Zizzo 3,4, Giovanni Martino 5, Francesca Sanguedolce 6, Andrea Marra 7, Barbara Crescenzi 8, Stefano A. Pileri 9 and Stefano Ascani 5

Abstract: A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis and developed a diffuse erythrodermic picture in the last two years. Systemic medications including prednisolone, acitretin, anti-IL17 (ixekizumab), TNF inhibitor (adalimumab), anti-IL23 (guselkumab), methotrexate, cyclosporine, and phosphodiesterase 4 inhibitor (apremilast) were ineffective. Repeated skin biopsies excluded mycosis fungoides, confirming psoriasis; molecular analysis of T-cell receptor genes ruled out clonality. The axillary lymph node histology documented a dermatopathic lymphadenitis, often associated with chronic cutaneous inflammatory diseases. At an accurate morphological evaluation, features of HHV8-positive multicentric Castleman disease were observed. Moreover, in a few follicles, in situ mantle cell neoplasia was identified. The translocation t(11;14)(q13;q32), characteristic of mantle cell lymphoma, and the monoclonal IGH gene rearrangement were present. HHV8 DNA was identified on plasma sample. Multicentric Castleman disease in psoriatic patients is a rare event and it might be favored by the immunomodulatory treatment in longstanding psoriasis. Multicentric Castleman disease patients are predisposed to developing simultaneous or subsequent lymphoma. In situ mantle cell neoplasia often behaves indolently, although it may progress to overt mantle cell lymphoma. Rituximab achieved a good control of psoriasis. Unfortunately, the patient developed Staphylococcus aureus sepsis for which he is currently on antibiotic therapy.

Keywords: psoriasis; castleman disease; HHV8; mantle cell; lymphoma; dermatopathic lymphadenitis
Topic and systemic medications including prednisolone, acitretin, anti-IL17 (ixekizumab), TNF inhibitor (adalimumab), anti-IL23 (guselkumab), methotrexate, cyclosporine, and phosphodiesterase 4 inhibitor (apremilast) obtained little benefit. Repeated skin biopsies ruled out mycosis fungoides, as the histopathology was consistent with psoriasis and molecular analysis excluded T-cell receptor (TCR) gene clonality.

The excised axillary lymph node showed distinctive reactive features of dermatopathic lymphadenitis with paracortical hyperplasia and melanin-pigmented macrophages (Figure 2), typically seen in chronic cutaneous inflammatory diseases.

Additionally, atrophic, hyalinized germinal centers with prominent penetrating venules (Figure 3) and interfollicular polytypic plasma cells were noted. Scattered Human Herpesvirus 8 (HHV8)-positive cells (Figure 4) within the mantle and interfollicular regions were identified. A subtle rim of cyclin D1-positive mantle cells was disclosed within few reactive-appearing follicles (Figure 5).
These findings were consistent with HHV8-positive multicentric Castleman disease (MCD) of mixed type associated with in situ mantle cell neoplasia (isMCN). The translocation t(11;14)(q13;q32) characteristic of mantle cell lymphoma (MCL) and the monoclonal IGH gene rearrangement were identified by fluorescence in situ hybridization (FISH) analysis and molecular study, respectively. HHV8 DNA (71 copies/mL) was identified by polymerase chain reaction (PCR) on the plasma sample.
The patient received infusions of the monoclonal antibody rituximab (375 mg/m², once every two weeks x four doses). Rituximab is also reported to be helpful in treating MCD [1]. The treatment was completed about a month before our case description, achieving good control of his psoriasis. Unfortunately, the patient developed Staphylococcus aureus sepsis, for which he is currently on antibiotic treatment.

According to the current 2017 World Health Organization (WHO) classification, HHV8-positive MCD belongs to HHV8-associated lymphoproliferative disorders [1–5].

MCD commonly occurs in immunosuppressed patients, being often reported in association with HIV infection, but it may also develop in HIV-negative individuals, especially originating from HHV8-endemic regions [1]. MCD is usually negative for Epstein Barr virus, whereas it is strongly associated with Human Herpes virus 8 (HHV8) infection, detected in almost all HIV-positive cases and in 50% of HIV-negative ones [1].

It presents often with constitutional symptoms (e.g., fever, asthenia, weight loss), generalized lymphadenopathy, splenomegaly and hepatomegaly [1]. Laboratory tests reveal cytopenia, hypoalbuminemia, hypergammaglobulinemia, elevated serum levels of inflammatory markers (C-reactive protein and IL-6) [1]. It usually follows an unfavorable outcome [1].

In patients with psoriasis, HHV8-positive MCD is very rarely reported [6]. Its emergence has been supposed to be linked to the immunomodulatory treatment, particularly in severe and longstanding psoriasis [6]. It is worth mentioning the relevance of discussing with the patient about possible risks and benefits of the immunomodulatory treatment, as it was adequately done in the present case.

MCD patients have an increased risk of developing simultaneous or subsequent lymphomas of different subtypes, which generally follow an aggressive course [1,7–9].

MCL is a non-Hodgkin B-cell lymphoma, traditionally considered an aggressive disease, although more indolent forms, including isMCN, are currently well known [1].

isMCN represents a rare event, usually identified incidentally. It generally follows an indolent course, although it may rarely progress to overt MCL after many years [1].

isMCN has been exceptionally reported in association with Castleman disease [10].
Author Contributions: Conceptualization, M.Z. (Magda Zanelli) and S.A.; methodology, M.Z. (Magda Zanelli), L.S., and S.A.; investigation, B.C. and L.S.; data curation, A.M., F.S., G.M., and M.Z. (Maurizio Zizzo); writing—original draft preparation, M.Z. (Magda Zanelli); writing—review and editing, M.Z. (Magda Zanelli); supervision, S.A. and S.A.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Ethical review and approval were waived for this study, due to the description of a single case.

Informed Consent Statement: Informed consent was obtained from the patient involved in the study.

Data Availability Statement: The data presented in this study are available from the corresponding author upon request.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Said, J.; Isaacson, P.G.; Campo, E.; Harris, N.L. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed.; WHO Classification of Tumours Editorial Board, Ed.; IARC: Lyon, France, 2017; pp. 325–327.
2. Zanelli, M.; Sanguedolce, F.; Zizzo, M.; Palicelli, A.; Bassi, M.C.; Santandrea, G.; Martino, G.; Soriano, A.; Caprera, C.; Corsi, M.; et al. Primary effusion lymphoma occurring in the setting of transplanted patients: A systematic review of a rare, life-threatening post-transplantation occurrence. BMC Cancer 2021, 21, 468. [CrossRef] [PubMed]
3. Zanelli, M.; Zizzo, M.; Bisagni, A.; Froio, E.; De Marco, L.; Valli, R.; Filosa, A.; Luminari, S.; Martino, G.; Massaro, F.; et al. Germinotropic lymphoproliferative disorder: A systematic review. Ann. Hematol. 2020, 99, 2243–2253. [CrossRef] [PubMed]
4. Zanelli, M.; Fraternali Orcioni, G.; Zizzo, M.; De Marco, L.; Martino, G.; Cerrone, G.; Cabras, A.D.; Ascani, S. HHV-8-and EBV-positive germinotropic lymphoproliferative disorder. Ann. Hematol. 2019, 98, 2439–2441. [CrossRef] [PubMed]
5. Zanelli, M.; Bertuzzi, C.; Zizzo, M.; Martin, G.; Sabattini, E.; Ascani, S. Extracavitary primary effusion lymphoma in a post-transplantation patient. Br. J. Hematol. 2019, 187, 555. [CrossRef] [PubMed]
6. Mohagheghi, M.A.; Omranipur, R.; Ensani, F.; Ghannadan, A.; Shahriaran, S.; Samiee, F.; Sedighi, Z. A case of advanced unicentric retroperitoneal Castleman’s disease associated with psoriasis. Acta Med. Iran. 2017, 55, 277–279. [PubMed]
7. Larroche, C.; Cacoub, P.; Soulier, J.; Oksenhendler, E.; Clauvel, J.P.; Piette, J.C.; Raphael, M. Castleman’s disease and lymphoma: Report of eight cases in HIV-negative patients and literature review. Am. J. Hematol. 2002, 69, 119–126. [CrossRef] [PubMed]
8. Parente, P.; Zanelli, M.; Zizzo, M.; Covelli, C.; Carosi, I.; Ascani, S.; Graziano, P. Primary effusion lymphoma metachronous to multicentric Castleman disease in an immunocompetent patient. Pathol. Res. Pract. 2020, 216, 153024. [CrossRef] [PubMed]
9. Yoshida, T.; Sakai, A.; Imagawa, J.; Noda, M.; Takada, S.; Yoshino, T.; Kimura, A. Mantle cell lymphoma superimposed on multicentric Castleman’s disease. J. Clin. Exp. Hematopathol. 2011, 51, 147–150. [CrossRef]
10. Dobrea, C.; Mihai, M.; Danaila, E.; Gaman, A.; Coriu, D.; Ursuleac, I. “In situ” mantle cell lymphoma associated with hyaline-vascular Castleman disease. Rom. J. Morphol. Embryol. 2011, 52, 1147–1151.